Importance of Dosing Regimen for the Effect of Vitamin D Supplementation

University of Tromso (UiT)

Status and phase: Completed; Phase 3

Conditions: Hypovitaminosis D

Treatments: Drug: Placebo; Drug: Vitamin D

Study type: Interventional

Funder types: Other

Identifiers

NCT03272126

TromsøEndo-2017-1

Details and patient eligibility

About

Vitamin D is a hormone with effects not only on the skeleton, but on most tissues in the body. Lack of vitamin D is associated with cardio-vascular disease (CVD), type 2 diabetes, cancer, infectious and immunological diseases, as well as risk factors for these diseases. However, intervention studies with vitamin D have been inconclusive regarding diseases and risk factors. This could be due to inclusion of subjects already vitamin D sufficient, and short and underpowered studies. In addition, there are indications that the dosing regimens may be important, so that daily doses with vitamin D are more efficient than intermittent doses, which so far have been generally used. This could be related to the concentration of circulating and thereby intracellular vitamin D concentrations, which probably is dependent on daily vitamin D doses. This will be tested in the present study where 60 subjects will be randomized to vitamin D 160 000 once, vitamin D 4000 IU/day, or placebo for four weeks. The primary endpoints will be effects on serum hepcidin and plasma cathelicidin after 4 weeks, with effects on serum PTH, RNA expression and microRNA in peripheral blood, telomerase activity in peripheral blood mononuclear cells and the ration between serum 1,25(OH)2D and 24,25(OH)2D as secondary endpoints.

Enrollment: 61 patients

Sex: All

Ages: 20 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:- Males and females 20 - 70 years

• 20 kg/m2 > BMI < 35 kg/m2
• systolic BP < 175 mmHg, diastolic BP < 105 mmHg
• Serum 25(OH)D level < 50 nmol/L. Serum 25(OH)D < 50 nmol/L is considered as vitamin D deficiency, and accordingly, effects of vitamin D supplementation will be easier to detect than if the included subjects were vitamin D sufficient.
• Hgb, SR, CRP, creatinine < 130 umol/L in males, < 120 umol/L in females, calcium, FT4 and TSH within the normal reference range; ASAT < 90 mU/L ALAT < 140 U/L, HbA1c < 6.6 %
• The subjects must agree not to take any vitamin D supplementation, including cod liver oil or "mølje", use solarium or go on sunny vacation during the intervention period.

Exclusion Criteria:

• subjects allergic to peanuts
• subjects with primary hyperparathyroidism
• granulomatous diseases (sarcoidosis, tuberculosis, Wegner's granulomatosis)
• diabetes
• renal stones the last five years
• subjects seriously ill (or with chronic disease) and unfit for participation in the study (as judged by one of the study doctors)
• subjects using vitamin D supplements exceeding 800 IU per day or active vitamin D drugs (Rocaltrol or Etalpha)
• pregnancy

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

61 participants in 3 patient groups, including a placebo group

vitamin D bolus

Experimental group

Description:

vitamin D 160 000 IU given as bolus

Treatment:

Drug: Vitamin D

vitamin D daily

Experimental group

Description:

vitamin D 4000 IU daily for 28 days

Treatment:

Drug: Vitamin D

placebo

Placebo Comparator group

Description:

identical looking as vitamin d

Treatment:

Drug: Placebo